<?xml version="1.0" encoding="UTF-8"?>
<p id="Par26">Expectedly, development of neutralizing antibodies may take less time due to their speedy trials and high specificity, as a prompt option repurposing of broad spectrum antiviral agents and their combinations is being frantically evaluated.</p>
